Overview

A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer

Status:
Recruiting
Trial end date:
2027-01-30
Target enrollment:
Participant gender:
Summary
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
280Bio Inc
Treatments:
Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel